Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.

Abstract:

INTRODUCTION:Treatment of complicated intra-abdominal infections (cIAIs) is becoming increasingly difficult because of the widespread emergence of multidrug-resistant organisms. AREAS COVERED:In this review, we discuss the effectiveness of several new antibiotics for the treatment of cIAIs, including new β-lactamase inhibitor combinations (BLICs) and tetracycline-class drugs, recently developed aminoglycosides and quinolones, and novel lipoglycopeptides and oxazolidinones. EXPERT OPINION:Of the new BLICs, ceftolozane/tazobactam is associated with adequate clinical cure rates in patients with cIAIs. Currently, two new β-lactamase inhibitors, namely avibactam and MK-7655, are under development for clinical use in the treatment of cIAIs. Eravacycline, a novel, fully synthetic tetracycline-class drug, has been shown in Phase II and III clinical trials to be more potent than tigecycline against a significant number of multidrug-resistant organisms causing cIAIs. Plazomicin, a next-generation aminoglycoside, is a promising agent for treatment of cIAIs due to multidrug-resistant pathogens. Of the recently developed quinolones, delafloxacin and finafloxacin have been shown to be effective against pathogens that survive and multiply in mildly acidic environments, although further clinical studies examining their clinical utility in the treatment of cIAIs are warranted. Oritavancin, a new semisynthetic lipoglycopeptide agent, has been demonstrated to be a potent antibiotic in the treatment of cIAIs due to drug-resistant Gram-positive organisms. Several other new antibiotics in development also show promise and will hopefully broaden the possibilities for treatment of complicated intra-abdominal infections due to MDR pathogens.

authors

Lin SY,Huang CH,Ko WC,Chen YH,Hsueh PR

doi

10.1517/14656566.2016.1122756

subject

Has Abstract

pub_date

2016-01-01 00:00:00

pages

339-54

issue

3

eissn

1465-6566

issn

1744-7666

journal_volume

17

pub_type

杂志文章,评审
  • Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease.

    abstract:INTRODUCTION:Bronchodilators represent the mainstay of symptomatic treatment for chronic obstructive pulmonary disease (COPD). The principal bronchodilator agents are β(2)-agonists, anticholinergics and methylxanthines, used singly or in combination. Indacaterol is a novel long-acting β(2)-agonist for maintenance bronc...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.2012.674513

    authors: Steiropoulos P,Papanas N,Nena E,Bouros D

    更新日期:2012-05-01 00:00:00

  • Management of incomplete remission and treatment resistance in first-episode psychosis.

    abstract:BACKGROUND:Incomplete remission and treatment resistance are common even in first-episode psychosis patients. OBJECTIVE:The aim of this review was to provide an overview of the available interventions and treatment pathways for the management of incomplete remission and treatment resistance in first-episode psychosis....

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.12.2039

    authors: Lambert M,Naber D,Huber CG

    更新日期:2008-08-01 00:00:00

  • Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future.

    abstract::Maximal surgical debulking and radiotherapy have been the cornerstone of therapy for high-grade gliomas. The impact of chemotherapy on outcome has been marginal and, until recently, its usage has been debatable. The development of new drugs and an improved understanding of chemoresistance have reinvigorated interest i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.6.749

    authors: Cavaliere R,Newton H

    更新日期:2006-04-01 00:00:00

  • The value of irbesartan in the management of hypertension.

    abstract::Elevated blood pressure levels are highly prevalent and are a major reason for cardiovascular events and thus place a significant financial burden on healthcare systems worldwide. Guidelines recommend five first-line anti-hypertensive drug classes, but compelling indications may indicate favoring one drug class over a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903103820

    authors: Bramlage P,Durand-Zaleski I,Desai N,Pirk O,Hacker C

    更新日期:2009-08-01 00:00:00

  • Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes.

    abstract::Insulin glulisine (Apidra, Sanofi-Aventis), a new and recently approved rapid-acting insulin analogue, mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin, but has a rapid onset, peak effect at 1h, and a shorter duration of action (approximately 4 h). Its rapid-action properties are ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.4.643

    authors: Garg SK,Ellis SL,Ulrich H

    更新日期:2005-04-01 00:00:00

  • Current and future therapies for the treatment of histamine-induced angioedema.

    abstract:INTRODUCTION:Angioedema, a sudden, self-limited swelling of localized areas of any part of the body that may or may not be associated with urticaria, is thought to be the result of a mast-cell mediated process versus a bradykinin etiology. Understanding the mechanism is key in determining the proper treatment. Areas Co...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1282461

    authors: James C,Bernstein JA

    更新日期:2017-02-01 00:00:00

  • The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction.

    abstract:OBJECTIVE:To investigate the impact of daily sildenafil on levels of soluble molecular markers of endothelial function in men with erectile dysfunction. METHODS:Patients aged >18 years with erectile dysfunction of vascular etiology for >6 months, either alone or in combination with disease states strongly associated w...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560802678211

    authors: Konstantinopoulos A,Giannitsas K,Athanasopoulos A,Spathas D,Perimenis P

    更新日期:2009-02-01 00:00:00

  • Assessment and management of acute pain in high-risk neonates.

    abstract::Neonates in the neonatal intensive care unit experience hundreds of painful procedures at a time of rapid neurological development. Although the immediate responses to pain may be protective, the potential long-term effects of early and under-treated pain are concerning. As pain assessment is the first step in the pro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.4.475

    authors: Gibbins S,Stevens B,Asztalos E

    更新日期:2003-04-01 00:00:00

  • Neratinib for the treatment of breast cancer.

    abstract:INTRODUCTION:Neratinib is an orally available, pan-HER inhibitor with clinical activity in patients with HER2-amplified and HER2-mutated breast cancer. Areas covered: A summary of publically available and relevant clinical data on neratinib. Expert opinion: Neratinib (N) is clearly distinct from lapatinib (L), a differ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2016.1244528

    authors: Prové A,Dirix L

    更新日期:2016-11-01 00:00:00

  • Apremilast as a treatment for psoriasis.

    abstract:INTRODUCTION:Psoriasis is a common skin disorder characterized by chronic inflammatory lesions that are frequently vexing for patients and difficult for physicians to treat. Although multiple therapeutic options are available, all have limitations. Topical preparations have issues with patient adherence, as compared to...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.699959

    authors: Shutty B,West C,Pellerin M,Feldman S

    更新日期:2012-08-01 00:00:00

  • Ceftazidime for respiratory infections.

    abstract:INTRODUCTION:Ceftazidime is a third-generation cephalosporin that has activity against Gram-negative bacilli, including Pseudomonas aeruginosa. The increasing prevalence of antimicrobial resistance and the limited number of antimicrobial agents in development have necessitated a review of the current status of treatmen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.721777

    authors: Choi SH,Koh Y

    更新日期:2012-10-01 00:00:00

  • Photodynamic therapy using 5-aminolaevulinic acid for the treatment of dysplasia in Barrett's oesophagus.

    abstract:BACKGROUND:5-Aminolaevulinic acid (ALA) is the naturally occurring metabolic precursor of an endogenously formed photosensitiser, protoporphyrin IX. It is used topically to treat benign and malignant skin disorders by a process called photodynamic therapy (PDT). Recently, data are emerging on its systemic use in the tr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.5.851

    authors: Dunn J,Lovat L

    更新日期:2008-04-01 00:00:00

  • Treatment modalities for bacterial rhinosinusitis.

    abstract:IMPORTANCE OF THE FIELD:Rhinosinusitis is a common illness that represents a substantial economic burden. The vast majority of cases resolve spontaneously but a small proportion develops a secondary bacterial infection. Accurate diagnosis of rhinosinusitis depends upon clinical assessment. Isolation of the causative ag...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656561003598901

    authors: Brook I

    更新日期:2010-04-01 00:00:00

  • Pharmacological treatment for insomnia in patients with major depressive disorder.

    abstract:INTRODUCTION:Insomnia in Major Depressive Disorder (MDD) is highly prevalent and associated with increased suffering and functional impairment. Effective, evidence-based treatments for insomnia in MDD are an unmet need in clinical practice. AREAS COVERED:Herein, the authors provide a review of the clinical correlates,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1614562

    authors: Brietzke E,Vazquez GH,Kang MJY,Soares CN

    更新日期:2019-08-01 00:00:00

  • Daily versus intermittent corticosteroids for the treatment of mild persistent asthma.

    abstract::Asthma is a chronic disease of the airways in which inflammation causes bronchial hyper-reactivity and attacks of wheezing, dyspnea and chest tightness that are triggered by various agents. It requires both acute treatment of the paroxistical respiratory symptoms with reliever medications and maintenance treatment, wh...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.7.9.1235

    authors: Antoniu SA

    更新日期:2006-06-01 00:00:00

  • Pharmacotherapeutic strategies for managing comorbid depression and diabetes.

    abstract::Introduction: The increasing prevalence of comorbid depression and diabetes exerts a heavy burden on global health. Co-occurrence of depression and diabetes is common, affecting 14% to 35.8% of patients with diabetes, leading to a higher mortality and morbidity rate, more micro- and macro-vascular diseases and more co...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1622090

    authors: Li HQ,Chi S,Dong Q,Yu JT

    更新日期:2019-09-01 00:00:00

  • Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.

    abstract:INTRODUCTION:Increasing population age, obesity and physical inactivity mean that type 2 diabetes mellitus (T2DM) is increasingly common. Current treatments may be limited by adverse events, drug-drug interactions or contraindication/need for dose adjustment in patients with renal impairment. AREAS COVERED:This paper ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.642863

    authors: Forst T,Pfützner A

    更新日期:2012-01-01 00:00:00

  • Fluticasone propionate: a potent inhaled corticosteroid for the treatment of asthma.

    abstract::Fluticasone propionate (FP) is a potent inhaled corticosteroid (ICS) for the treatment of asthma. It is currently marketed in both the United States (as Flovent) and Europe (as Flixotide). Fluticasone is available in both aerosolised metered dose inhaler (MDI) and dry powder devices, with dosages ranging from 44-500 m...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.6.1227

    authors: Staresinic AG,Sorkness CA

    更新日期:2000-09-01 00:00:00

  • 1st International Conference on Panic Attacks: diversity of theories and treatments. september 5-8, 2003, London.

    abstract::The 1st International Conference on Psychophysiology of Panic Attacks focused on the diversity of treatments and theories in this complex condition. Experimental research topics were featured, as well as treatment strategies, case studies and patient perspectives. The conference aimed to create a strong multi-cultural...

    journal_title:Expert opinion on pharmacotherapy

    pub_type:

    doi:10.1517/14656566.5.4.977

    authors: Perry D

    更新日期:2004-04-01 00:00:00

  • Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.

    abstract:INTRODUCTION:Tubulin inhibitors including taxanes and vinca alkaloids are important components of chemotherapy regimens used in advanced non-small cell lung cancer (NSCLC). Despite a treatment paradigm shift due to molecularly-targeted therapies and immunotherapy, a majority of patients will receive chemotherapy during...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1316374

    authors: Hardin C,Shum E,Singh AP,Perez-Soler R,Cheng H

    更新日期:2017-05-01 00:00:00

  • A new ketoconazole topical gel formulation in seborrhoeic dermatitis: an updated review of the mechanism.

    abstract::Seborrhoeic dermatitis (SD) is a chronic, inflammatory skin disorder, affecting areas of the head and body where sebaceous glands are most prominent and active. The disorder commonly affects hair-bearing areas of the head, including the scalp. Involvement on the face is usually limited to the hairline, eyebrows, nasol...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.9.1365

    authors: Faergemann J,Borgers M,Degreef H

    更新日期:2007-06-01 00:00:00

  • A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer.

    abstract::Following Huggins' original observation of the dependence of the prostate on androgens, testosterone suppression by either orchiectomy or oestrogen compounds (e.g., diethylstilbesterol [DES]) became the standard palliative treatment for advanced prostate cancer. Early studies showed testosterone suppression improved s...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.2.447

    authors: Perez-Marrero R,Tyler RC

    更新日期:2004-02-01 00:00:00

  • Association between antidepressants and breast/ovarian cancer.

    abstract:INTRODUCTION:Women are more vulnerable to the development of major depressive disorder (MDD) than men. Although several epidemiological studies have investigated the association between antidepressants and the risk of developing cancer, different methodologies were applied and as a result most of the results were incon...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,杂志文章

    doi:10.1517/14656566.2012.647684

    authors: Pae CU

    更新日期:2012-02-01 00:00:00

  • Sustained release oral fampridine in the treatment of multiple sclerosis.

    abstract:BACKGROUND:Fampridine-SR is under submission as the first drug to be FDA approved with an indication specifically for multiple sclerosis symptoms. Compounded forms of the active agent of Fampridine-SR (4-aminopyridine) have been used in clinical practice for many years. Clinical trials have now been completed that demo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903075994

    authors: Kachuck NJ

    更新日期:2009-08-01 00:00:00

  • New pharmacological approaches for the treatment of alcoholism.

    abstract::Pharmacological relapse prevention in alcoholism is a rather new clinical field with few drugs being available. Acamprosate, acting predominantly via glutamatergic pathways, and the opioid receptor antagonist naltrexone, were both shown to be efficient in improving rates for continuous abstinence, and not relapsing to...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.17.2341

    authors: Soyka M,Roesner S

    更新日期:2006-12-01 00:00:00

  • An evaluation of tofacitinib for the treatment of psoriatic arthritis.

    abstract::Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory condition that is associated with progressive joint destruction and reduced quality of life. Despite the common use of disease-modifying anti-rheumatic drugs (DMARDs) in PsA, their influence has been investigated in a number of studies with conflicting ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1657404

    authors: Abdulrahim H,Sharlala H,Adebajo AO

    更新日期:2019-11-01 00:00:00

  • Strategies in the treatment of HIV-1-associated adipose redistribution syndromes.

    abstract::HIV-1/highly active antiretroviral therapy-associated lipodystrophy syndrome (HALS) is presently the most common long-term adverse effect limiting the doubtless efficacy of antiretroviral therapy. It has a great impact on the quality of life of patients, it is stigmatising and its psychologically devastating consequen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.12.1871

    authors: del Mar Gutierrez M,Mateo G,Domingo P

    更新日期:2007-08-01 00:00:00

  • The role of infectious agents in pulmonary and systemic vascular disease.

    abstract::With emphasis on the pulmonary circulation, three general types of vascular disease are discussed: fibroproliferative (atherosclerosis), cellular proliferative (endothelial neoplasms) and inflammatory (granulomatous vasculitis). The causes of these phenotypic responses are invariably multifactorial, but infectious age...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.7.1093

    authors: Egermayer P

    更新日期:2001-07-01 00:00:00

  • The pharmacological management of hairy cell leukemia.

    abstract:INTRODUCTION:Hairy cell leukemia (HCL) is a B-cell lymphoid malignancy that accounts for approximately 2% of all leukemias. Treatment with purine nucleoside analogs (PNA) results in a high response rate and remains the standard of care. Long term follow-up shows that most patients relapse and require retreatment. Newer...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1754397

    authors: Ramos Perez J,Ravandi-Kashani F

    更新日期:2020-08-01 00:00:00

  • Current and emerging drug treatment strategies for peripheral arterial disease.

    abstract:INTRODUCTION:Peripheral artery disease (PAD) is a prevalent but underdiagnosed manifestation of atherosclerosis that has a worse prognosis than coronary artery disease. Patients with PAD are at heightened risk of both systemic cardiovascular adverse events and limb-related morbidity. There is insufficient awareness of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1774556

    authors: Essa H,Torella F,Lip GYH

    更新日期:2020-09-01 00:00:00